Commercializing Medical AI Technologies: Challenges and Opportunities
Artificial intelligence (AI) is making a real difference in healthcare. For instance, AI-guided imaging is improving how vascular diseases—conditions affecting over 200 million people worldwide—are diagnosed and treated. A recent AI algorithm enables nurses without ultrasound training to accurately diagnose abdominal aortic aneurysms (AAA), matching the performance of trained physicians. This can boost AAA screening, but turning AI innovations into clinical realities requires smart commercialization strategies. These include securing funding, meeting regulatory standards, gaining health technology assessments, securing reimbursement, and integrating into clinical guidelines.
Introduction
Vascular diseases such as carotid, aortic, and peripheral artery disease cause serious health issues like aneurysm rupture, stroke, and limb loss. Specialists rely heavily on imaging tools like ultrasound, CT, and fluoroscopy for diagnosis and treatment. While AI tools are becoming more common, their routine use in vascular imaging is still limited. Challenges around finances, regulations, and implementation slow clinical adoption. Many AI models are developed without aligning to regulatory or quality standards, blocking their path to practice.
Abdominal aortic aneurysms, for example, are often found incidentally rather than through active screening, despite guidelines recommending it. Undetected AAAs can rupture with mortality rates reaching 80%. AI-enhanced imaging could increase screening rates and enable timely intervention before rupture. In this article, we focus on an AI deep learning tool for AAA screening and explore the broader challenges and opportunities in commercializing medical AI.
From Algorithm to Impact: A Validated AI Tool for Aneurysm Screening
Ultrasound screening for AAA is underperformed worldwide, mainly due to shortages of trained technicians, especially in low-resource settings. A recent AI tool helps nurses without ultrasound training detect AAA with 100% sensitivity and 97.8% specificity. The algorithm guides probe placement and automatically measures the aorta’s maximal diameter in real time.
In a study of 184 patients at a cardiology clinic in Taiwan, nurses using the AI completed scans in just 37 seconds on average. Nearly 88% of scans were diagnostically sufficient, matching the quality of those by trained physicians. This technology shows promise for increasing AAA screening in underserved areas. However, expert oversight remains essential to ensure accuracy and safety. Larger, diverse studies are needed to confirm the tool's generalizability.
Beyond validation, achieving clinical impact demands careful attention to commercialization steps: funding, regulatory compliance, health technology assessment, reimbursement, and clinical guideline integration.
Opportunities and Lessons from Successful Medical AI Commercialization
Several companies have successfully brought medical AI products to market. One US-based firm founded in 2016 began with neurological care AI and expanded into cardiovascular, trauma, and oncology. They developed multiple FDA-cleared AI algorithms analyzing CT scans, ECGs, and echocardiograms, supporting diagnosis and treatment in conditions like cerebral aneurysm, ischemic stroke, and AAA.
Key factors behind their success include:
- A multidisciplinary team of clinicians and engineers collaborating closely.
- Following standardized medical device development processes, including ISO certifications.
- Early health technology assessments demonstrating cost savings, for example, $11 million/year saved in the UK on ischemic stroke detection.
- Securing substantial investment—over $290 million—to build and scale products.
- Obtaining FDA clearance by integrating regulatory considerations throughout development.
- Working with US payers to create billing codes, enabling reimbursement (e.g., $1040 per patient for AI-based stroke detection).
This pathway illustrates the importance of persistence, mentorship, and collaboration. With over 1000 FDA-approved AI medical devices to date, regulatory approval and commercialization are achievable goals.
Financial, Regulatory, and Implementation Barriers
Investment and Funding
Many AI projects stall after initial development due to insufficient funding for product scaling. Academic grants typically cover prototype creation but not deployment. Private investors expect compelling evidence of clinical and economic value, not just model performance.
For niche conditions like AAA—affecting less than 5% of the global population—securing funding can be tough. Demonstrating how AI screening prevents costly emergencies and saves lives strengthens the commercial case. Additionally, adaptability to other vascular diseases broadens market potential.
Following Good Machine Learning Practice and quality standards from the start simplifies regulatory approval later. Maintaining thorough documentation is essential.
Obtaining Regulatory Approval
Regulations vary globally, but in the US, FDA clearance is mandatory for clinical use. The 510(k) pathway requires proving substantial equivalence to existing devices, often a complex process demanding extensive data. Early engagement with the FDA's Q-Submission Program can provide valuable feedback during development.
Regulatory planning should begin at product conception and continue throughout development to avoid costly setbacks.
Reimbursement Pathways
Most AI tools lack dedicated billing codes. Securing reimbursement requires collaboration with insurers, clinicians, and patients. Established billing structures can be hard to modify, so early stakeholder engagement is key.
Professional organizations can support these efforts, but expect the process to take years. Guidance from experienced mentors and active collaboration improve the chances of success.
Integration into Clinical Practice Guidelines
Clinical guidelines shape medical practice and validate new technologies. Engaging guideline committees to present evidence is crucial. For example, AAA screening recommendations differ between the Society for Vascular Surgery and the US Preventive Services Task Force, partly due to cost concerns.
AI-enhanced screening can lower costs and improve efficiency, potentially harmonizing guidelines and promoting wider adoption. Aligning clinical guidelines, reimbursement, and regulatory approval requires ongoing attention throughout product development.
Conclusions and Recommendations
Medical AI has clear potential to improve patient care, but success depends on more than algorithm accuracy. Effective commercialization demands strategic focus on investment, regulation, reimbursement, and clinical integration. Hundreds of AI algorithms exist, but few reach clinical use.
Product development professionals should prioritize building a solid regulatory and commercialization framework alongside technical innovation. This approach increases the chances of delivering AI tools that truly benefit healthcare systems and patients.
For those interested in advancing their knowledge of AI product development and commercialization, explore relevant courses and resources at Complete AI Training.
Your membership also unlocks:
